ArticleInvestigative ophthalmology & visual science2025
Overcoming Antimicrobial Resistance in Bacterial Keratitis With an Antibiotic-Eluting Contact Lens.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advancing Treatment of Degenerative Eye Diseases at the Nanoscale.Smart medicine · 2026Review
- Contemporary Research Questions in the Field of Contact Lenses and Where to Next?Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Purpose: Bacterial keratitis (BK) is a leading cause of corneal blindness globally, with an alarming rise in resistant infections. Current standard-of-care antibiotic eye drops or ointments suffer from low bioavailability and often fail to achieve therapeutic concentrations in cornea. This study evaluated a therapeutic contact lens (M-TCL) designed to provide sustained, localized high drug concentrations of moxifloxacin-a commonly used broad-spectrum antibiotic-as a potential treatment for drug-resistant BK. Methods: M-TCLs were engineered by encapsulating a thin moxifloxacin-polymer film within periphery of a contact lens hydrogel. Pharmacokinetics were assessed in rabbit ocular tissues and serum. Efficacy was evaluated using a rabbit keratitis model induced by clinical methicillin-resistant Staphylococcus aureus (MRSA) isolates that displayed in vitro resistance to moxifloxacin (minimum inhibitory concentration = 8 µg/mL). Biocompatibility was assessed through Draize testing and histological analysis. Results: In vitro, M-TCLs retained physical properties comparable to commercial contact lenses, sustained moxifloxacin release over 24 hours, and remained stable in a hydrated state for 12 months, enabling on-demand use. In rabbits, M-TCLs maintained higher corneal drug concentrations at all time points over 24 hours than the peak concentration from moxifloxacin drops (P = 0.03), with a 32-fold higher peak drug concentration and at least 11.3-fold greater area under the concentration-time curve (AUC(0-24 h)) in cornea. M-TCLs demonstrated bactericidal efficacy against MRSA keratitis with bacterial reduction of 3.86-log CFU/cornea (P < 0.0001), and mitigated keratitis-associated inflammation with lower aqueous humor protein levels (P = 0.01), compared to hourly moxifloxacin drops. M-TCLs were safe in rabbits. Conclusions: M-TCLs offer a promising therapy for BK and may serve as a potential therapy for drug-resistant BK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.